Theolytics

Theolytics is a clinical-stage biotechnology company based in Oxford, UK, founded in 2017. The company focuses on developing next-generation oncolytic immunotherapies using an adenovirus platform to target various cancers. By harnessing viruses, Theolytics aims to selectively kill cancer cells and activate the immune system, particularly through intravenous delivery for challenging solid tumors.

Theolytics has a dedicated team of around 20 experts in fields such as virology, cancer biology, and immunology. The company is backed by notable investors and has secured funding to support its clinical trials. Its lead candidate, THEO-260, is currently in Phase 1/2 clinical trials for platinum-resistant ovarian cancer. The company also has preclinical programs targeting colorectal cancer and hematological malignancies, with a focus on developing therapies that address high unmet medical needs.